Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 20

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 20
---
’s Directors and Executive Officers in the Arrangement — Canadian Securities Law Matters” for more information. As of the close of business on November 21, 2025, the Record Date, there were 43,108,362 Common Shares issued and outstanding. Approval of the Compensation Resolution requires the affirmative vote of a majority of the votes cast by Shareholders present in person or represented by proxy at the Special meeting. Approval of the Liquidation Resolution requires the affirmative vote of not less than 66 2⁄ 3% of the votes cast by Shareholders present in person (virtually) or represented by proxy at the Special Meeting. Approval of the Liquidator Resolution requires the affirmative vote of not less than 66 2⁄ 3% of the votes cast by Shareholders present in person (virtually) or represented by proxy at the Special Meeting.

5

Voting by Shareholders Any Registered Shareholder entitled to vote may submit a proxy by returning a signed proxy card by mail, through the internet or by telephone, or may vote in person (virtually) by attending the Special Meeting. If you are a Beneficial Shareholder and hold your Common Shares in “street name” through an Intermediary, you should instruct your Intermediary on how you wish your Common Shares to be voted using the instructions provided by such Intermediary. The Intermediary cannot vote on these proposals without your instructions. Therefore, it is important that you cast your vote or instruct your Intermediary on how you wish your Common Shares to be voted. If you are a street name holder and wish to vote the Common Shares beneficially owned by you in person (virtually) by ballot at the Special Meeting, you must provide a “legal proxy” from your Intermediary, giving you the right to vote the Common Shares at the Special Meeting. Recommendation of the Transaction Committee The Transaction Committee, with the advice and assistance of its independent legal and financial advisors, evaluated the Arrangement and the terms and conditions of the Agreement. At a meeting held on November 14, 2025, the Transaction Committee unanimously determined that the Consideration to be received by the Shareholders pursuant to the Arrangement is fair to the Shareholders and that the Arrangement is in the best interests of the Company. The Transaction Committee unanimously recommended that the Board (i) approve the Agreement; and (ii) recommend that the Shareholders vote “FOR” the Arrangement Resolution. Recommendation of the Board On November 14, 2025, based in